What is Regeneron's financial performance for the second quarter of 2007?

Regeneron reported a net loss of $26.8 million, or $0.41 per share, for the second quarter of 2007. This compares to a net loss of $23.6 million, or $0.41 per share, for the same period in 2006. While revenue increased to $22.2 million, operating expenses, particularly R&D, also rose significantly, leading to the wider net loss.

How has Regeneron's cash position changed?

The company's cash and cash equivalents decreased from $237.9 million at the end of 2006 to $109.6 million at June 30, 2007. This reduction is primarily due to increased investments in marketable securities and substantial funding of research and development activities.

What are the key clinical development updates for Regeneron?

Regeneron submitted a Biologics License Application (BLA) for rilonacept (IL-1 Trap) for Cryopyrin-Associated Periodic Syndromes (CAPS) to the FDA. Additionally, positive interim results from a Phase 2 trial for the VEGF Trap-Eye in wet Age-Related Macular Degeneration (AMD) were reported, and Phase 3 trials are now underway.

What significant licensing agreements has Regeneron entered into?

In February and March 2007, Regeneron entered into non-exclusive license agreements with AstraZeneca and Astellas Pharma Inc., respectively, for its VelocImmune® technology. Each agreement included a $20 million non-refundable upfront payment, which has been deferred and is being recognized as revenue over the license period.

REGN 10-Q Quarterly Report Q2 FY2007 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. reported a net loss of $26.8 million ($0.41 per share) for the second quarter of 2007, an increase from the $23.6 million net loss ($0.41 per share) in the same quarter of the previous year. This widening loss is attributed to increased operating expenses, primarily in research and development, which rose to $43.9 million from $34.4 million year-over-year. The company's revenue for the quarter saw a modest increase to $22.2 million from $19.3 million, driven by technology licensing revenue and contract research and development, partially offset by a decline in contract manufacturing revenue. Financially, the company ended the quarter with $109.6 million in cash and cash equivalents, down from $237.9 million at the end of 2006. This decrease is largely due to significant investments in marketable securities and ongoing operational expenses. Key developments include the submission of a Biologics License Application (BLA) for rilonacept for Cryopyrin-Associated Periodic Syndromes (CAPS) and positive interim results from Phase 2 trials for the VEGF Trap-Eye in wet Age-Related Macular Degeneration (AMD). The company also entered into significant license agreements with AstraZeneca and Astellas, generating substantial upfront payments now recorded as deferred revenue.

Key Highlights

1Net loss for Q2 2007 was $26.8 million ($0.41/share), compared to $23.6 million ($0.41/share) in Q2 2006.
2Total revenues increased to $22.2 million in Q2 2007 from $19.3 million in Q2 2006, driven by technology licensing and contract R&D.
3Research and development expenses increased significantly to $43.9 million in Q2 2007 from $34.4 million in Q2 2006.
4Cash and cash equivalents decreased to $109.6 million as of June 30, 2007, from $237.9 million as of December 31, 2006.
5Submitted a Biologics License Application (BLA) to the FDA for rilonacept for CAPS.
6Entered into non-exclusive license agreements with AstraZeneca and Astellas, receiving $20 million upfront payments from each.
7Positive interim results reported for the VEGF Trap-Eye Phase 2 trial in wet AMD.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2007

Summary

Key Highlights

Frequently Asked Questions